Skip to content
GLP-1 Decoder

Liraglutide: Uses, How It Works, Side Effects, Cost

Liraglutide is the active ingredient in Victoza and Saxenda, all from Novo Nordisk. The first Liraglutide brand, Victoza, was FDA approved in 2010.

Brands
Victoza and Saxenda
Manufacturer
Novo Nordisk
First brand approved
2010, Victoza
Best trial weight loss
7.4% (SCALE Obesity and Prediabetes)
FDA shortage
On the FDA shortage list
Liraglutide: a GLP-1 pen injector

Saxenda in brief

How long it lasts in your body
100%50%25%0%013 h26 h39 h2.2 d2.7 d50%25%12.5%time after the dose

Its half-life is about 13 hours: after 13 h, half is gone, while about 3% remains after five half-lives (2.7 d).

Main trial weight loss
Saxenda (SCALE Obesity and Prediabetes)7.4%Placebo3%

The SCALE Obesity trial (Prediabetes, 56 weeks) reported 7.4% of body weight, against 3% in the placebo group.

Sources: FDA label (DailyMed).

Liraglutide brands compared

One ingredient is used in different brands, and each has its own labeling, uses and pricing.

Sold in the US: every Liraglutide brand
BrandHow it is takenApproved forFirst approvedList price
Victozadaily injectionType 2 diabetes and heart risk2010$543.51 per 2 pens
Saxendadaily injectionWeight loss2014$1,349.02 per 5 pens

Pricing: Novo Nordisk 1 2. FDA label: 1 2.

What the Liraglutide trials showed

Liraglutide Results from the main trials
TrialWho took partLengthGroupAverage weight lossPlacebo
SCALE Obesity and PrediabetesAdults with obesity or overweight who do not have type 2 diabetes56 weeksLiraglutide 3.0 mg daily7.4%3%

Sources: FDA label (DailyMed), PubMed.

Liraglutide side effects

Compare within a column first because the labels tested different people and doses.

Liraglutide side effects for each brand at its highest labeled dose
Side effectVictozaSaxenda
Nausea20%39.3%
Diarrhea12%20.9%
ConstipationNot listed19.4%
Vomiting9%15.7%
Injection Site ReactionNot listed13.9%
Headache11%13.6%
Nasopharyngitis10%Not listed
Decreased appetite10%Not listed

Sources from labels: FDA (DailyMed) 1 2.

Source of these warnings: FDA label (DailyMed).

Generic and compounded Liraglutide

It remains on the current shortage list. In January 2027, Saxenda will leave the market. Currently, Supply of Victoza pens is limited and generic versions are on the market.

List of sources: api.fda.gov.

Every Liraglutide page